GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Synthetic MR AB (XSAT:SYNT) » Definitions » ROE %

Synthetic MR AB (XSAT:SYNT) ROE % : 16.01% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Synthetic MR AB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Synthetic MR AB's annualized net income for the quarter that ended in Dec. 2023 was kr18.33 Mil. Synthetic MR AB's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was kr114.50 Mil. Therefore, Synthetic MR AB's annualized ROE % for the quarter that ended in Dec. 2023 was 16.01%.

The historical rank and industry rank for Synthetic MR AB's ROE % or its related term are showing as below:

XSAT:SYNT' s ROE % Range Over the Past 10 Years
Min: -38.25   Med: 8.63   Max: 37.43
Current: 9.11

During the past 12 years, Synthetic MR AB's highest ROE % was 37.43%. The lowest was -38.25%. And the median was 8.63%.

XSAT:SYNT's ROE % is ranked better than
63.24% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.06 vs XSAT:SYNT: 9.11

Synthetic MR AB ROE % Historical Data

The historical data trend for Synthetic MR AB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthetic MR AB ROE % Chart

Synthetic MR AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.30 1.62 18.74 7.67 8.95

Synthetic MR AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 -8.41 13.40 14.79 16.01

Competitive Comparison of Synthetic MR AB's ROE %

For the Health Information Services subindustry, Synthetic MR AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthetic MR AB's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's ROE % distribution charts can be found below:

* The bar in red indicates where Synthetic MR AB's ROE % falls into.



Synthetic MR AB ROE % Calculation

Synthetic MR AB's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=10.014/( (107.127+116.572)/ 2 )
=10.014/111.8495
=8.95 %

Synthetic MR AB's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=18.332/( (112.431+116.572)/ 2 )
=18.332/114.5015
=16.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Synthetic MR AB  (XSAT:SYNT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=18.332/114.5015
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(18.332 / 120.476)*(120.476 / 138.527)*(138.527 / 114.5015)
=Net Margin %*Asset Turnover*Equity Multiplier
=15.22 %*0.8697*1.2098
=ROA %*Equity Multiplier
=13.24 %*1.2098
=16.01 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=18.332/114.5015
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (18.332 / 26.976) * (26.976 / 35.104) * (35.104 / 120.476) * (120.476 / 138.527) * (138.527 / 114.5015)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6796 * 0.7685 * 29.14 % * 0.8697 * 1.2098
=16.01 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Synthetic MR AB ROE % Related Terms

Thank you for viewing the detailed overview of Synthetic MR AB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthetic MR AB (XSAT:SYNT) Business Description

Traded in Other Exchanges
N/A
Address
Storgatan 11, Linkoping, SWE, SE-582 23
Synthetic MR AB develops innovative software solutions for Magnetic Resonance Imaging that supports shorter exam times and delivers more information to the clinician. Its product is available in different packages. SyMRI IMAGE provides high MRI workflows and enables automatic segmentation of brain tissue, providing objective decision support, MAGiC is a customer-specific version of SyMRI IMAGE marketed and sold by GE Healthcare under a licence agreement, SyMRI NEURO includes contrast images, biomarker segmentation, volumetric measurements of brain tissues and quantitative parametric maps, and SyMRI Research Edition includes contrast images, volumetric measurements and quantitative maps to provide more information to the researcher.

Synthetic MR AB (XSAT:SYNT) Headlines

From GuruFocus

Syntel to Present at Investor Conference

By Marketwired Marketwired 05-10-2018

Syntel Inc. (SYNT) Chairman, 10% Owner Bharat Desai sells 105,384 Shares

By GuruFocus Research GuruFocus Editor 12-16-2010

Syntel enters definitive agreement to be acquired by Atos S.E.

By GlobeNewswire GlobeNewswire 07-22-2018

Syntel Inc. (SYNT) CFO & CISO Arvind Godbole sells 2,175 Shares

By GuruFocus Research GuruFocus Editor 12-09-2010

Syntel to Present at Investor Conference

By Marketwired Marketwired 05-08-2018

Syntel Joins Google Cloud Partner Program

By Marketwired Marketwired 03-26-2018

A Solid Pick at a Fair Price

By Jae Jun Jae Jun 03-31-2015

Gurus Find Hot Information Technology Stocks

By James Li James Li 06-10-2016